使用透析充分性的多维测量——超越小分子溶质动力学
本综述讨论以Kt/Vurea为代表的小分子溶质清除作为透析剂量替代指标的局限,并代表美国肾脏病学会透析咨询组提出需验证一种超越小分子溶质动力学的多维测量,以量化由患者报告及综合临床和透析相关指标得出的最佳透析。
要点
- 小分子溶质清除(如Kt/Vurea)单独作为透析充分性指标不能完全量化透析治疗的预期临床效果。
- 美国肾脏病学会透析咨询组提出需验证一种超越小分子溶质动力学的多维测量。
- 该多维测量旨在纳入患者报告及综合临床和透析相关指标以量化最佳透析。
核心结论
- 依赖小分子溶质清除率单独作为透析充分性指标不能完全量化透析治疗的预期临床效果。
- 代表美国肾脏病学会透析咨询组,作者提出需确定一种超越小分子溶质动力学的多维测量的有效性和实用性,以量化由患者报告及综合临床和透析相关指标得出的最佳透析。
研究设计与样本
- 综述,旨在理解小分子溶质动力学作为透析剂量替代指标的优缺点,并呈现更全面的透析剂量构建前景。
主要发现
- 以Kt/Vurea为代表的小分子溶质清除已被广泛用于量化每周三次血液透析的剂量。
- 依赖小分子溶质清除率单独作为透析充分性指标不能完全量化透析治疗的预期临床效果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Urea removal has become a key measure of the intensity of dialysis treatment for kidney failure. Small solute removal, exemplified by Kt/Vurea, has been broadly applied as a means to quantify the dose of thrice weekly hemodialysis. Yet, the reliance on small solute clearances alone as a measure of dialysis adequacy fails fully to quantify the intended clinical effects of dialysis therapy. This review aims to (1) understand the strengths and limitations of small solute kinetics as a surrogate marker of dialysis dose, and (2) present the prospect of a more comprehensive construct for dialysis dose, one that considers more broadly the goals of ESRD care to maximize both quality of life and survival. On behalf of the American Society of Nephrology Dialysis Advisory Group, we propose the need to ascertain the validity and utility of a multidimensional measure that moves beyond small solute kinetics alone to quantify optimal dialysis derived from both patient-reported and comprehensive clinical and dialysis-related measures.
引用
- Perl J, Dember LM, Bargman JM, et al. The Use of a Multidimensional Measure of Dialysis Adequacy-Moving beyond Small Solute Kinetics. Clin J Am Soc Nephrol. 2017. PMID: 28314806. doi:10.2215/CJN.08460816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。